MK-8294-001

STX-478-101

BMS CA244-0001

MK-3120-002-00

DS2243-054

REGN7075

F60089IV101

IMA402-101

PANTUMOR 1479-0009

222730

ANV600-001

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

STX-721-101

D6900C00001

M22TGA

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

PROACTIVE

CyPep-1

VHIO17002

A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-8294 Monotherapy in Advanced Solid Tumors



<ul class="wp-block-list">
<li>Code NKI: M25MST</li>



<li>Code firma: MK-8294-001</li>



<li>Code clinicaltrials.gov: NCT07030712</li>
</ul>



Principal Investigator



T. Schutte



Drugs 



MK-8294 (Nectin-4 Tcell engager)



<h2 class="wp-block-heading">Summary</h2>



MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.



Read more on <a href="https://clinicaltrials.gov/study/NCT07030712" data-type="URL" data-id="https://www.clinicaltrials.gov/ct2/show/NCT05208762?term=SGNPDL1V-001&amp;draw=2&amp;rank=1">clinicaltrials</a><a href="https://www.clinicaltrials.gov/ct2/show/NCT05208762?term=SGNPDL1V-001&amp;draw=2&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/ct2/show/NCT05208762?term=SGNPDL1V-001&amp;draw=2&amp;rank=1">.gov</a>



<h2 class="wp-block-heading">Additional comments</h2>



Open